On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Lexaria Bioscience Corp. (LXRP) Well-Positioned for Growth as First Mover in Canada’s Cannabinoid Market

Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights

Among players in Canada’s emerging cannabinoid market, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth. Lexaria is a revenue-generating company engaged in developing and out-licensing proprietary technology for delivering bioactive compounds, including cannabinoids, and the company’s products utilize this patented lipophilic technology, which has been proven to enhance the bioavailability of orally ingested cannabinoids and also improve their taste.

“With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.”

To view the full article, visit http://nnw.fm/3jmRt

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com

More from NetworkNewsBreaks

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Moves Closer to Kimmett Expansion with TSXV Approval of Cannabis Wheaton Investment

Cerus Corp. (NASDAQ: CERS) Partners with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Says Cigna will Cover ThyGenX® Nationwide

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217